Contact
searchSearch
HMP Global
Login
Quiz

ADC Performance in HR-Positive, HER2-Negative Metastatic Breast Cancer

08/21/2025

Related Content

News
De-escalated Paclitaxel, Trastuzumab, and Pertuzumab Yield Excellent Long-Term Outcomes in HER2-Positive Breast Cancer
07/14/2026
Stephanie Holland
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the...
07/14/2026
Oncology
Robert Stein, PhD
Videos
Prosigna-Guided Treatment Safely Reduces Chemotherapy Use in HR-Positive, HER2-Negative Early Breast Cancer
06/19/2026
Robert Stein, PhD
Robert Stein, PhD, discusses results from the phase 3 OPTIMA trial showing that Prosigna-guided treatment identified approximately 68% of patients with HR-positive, HER2-negative early breast cancer who could safely avoid chemotherapy without...
Robert Stein, PhD, discusses results from the phase 3 OPTIMA trial showing that Prosigna-guided treatment identified approximately 68% of patients with HR-positive, HER2-negative early breast cancer who could safely avoid chemotherapy without...
Robert Stein, PhD, discusses...
06/19/2026
Oncology
Mabel Mardones, MD
Videos
Giredestrant Demonstrates Favorable Safety Profile but Fails to Significantly Improve PFS in HR-Positive, HER2-Negative Metastatic Breast Cancer
06/18/2026
Mabel Mardones, MD
Mabel Mardones, MD, discusses results from the phase 3 persevERA trial which showed that giredestrant plus palbociclib achieved a numerical progression-free survival improvement over letrozole plus palbociclib but did not meet the study’s...
Mabel Mardones, MD, discusses results from the phase 3 persevERA trial which showed that giredestrant plus palbociclib achieved a numerical progression-free survival improvement over letrozole plus palbociclib but did not meet the study’s...
Mabel Mardones, MD, discusses...
06/18/2026
Oncology

Recent News

News
Response-Guided PD-1 Therapy May Support Treatment De-Escalation in Advanced Cutaneous Squamous Cell Carcinoma
08/28/2026
Emily Estrada
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A retrospective cohort study...
08/28/2026
Oncology
News
Ivonescimab Plus Chemotherapy Extends PFS After Tyrosine Kinase Inhibitor Progression in EGFR-Mutant Non-Small Cell Lung Cancer
08/28/2026
Stephanie Holland
Results from the phase 3 HARMONi trial showed that ivonescimab plus pemetrexed and carboplatin significantly improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutant non-small cell lung cancer...
Results from the phase 3 HARMONi trial showed that ivonescimab plus pemetrexed and carboplatin significantly improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutant non-small cell lung cancer...
Results from the phase 3 HARMONi...
08/28/2026
Oncology
News
Expert Consensus Establishes Imaging Recommendations for High-Risk Cutaneous Squamous Cell Carcinoma
08/28/2026
Emily Estrada
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A multidisciplinary Delphi...
08/28/2026
Oncology
News
Twice-Daily Radiation Associated With Better Patient-Reported Outcomes in Limited-Stage Small Cell Lung Cancer
08/27/2026
Emily Estrada
A planned patient-reported outcomes analysis from NRG-LU005 found that adding atezolizumab to chemoradiation did not significantly reduce clinically meaningful decline at 15 months, while twice-daily radiation was consistently associated with...
A planned patient-reported outcomes analysis from NRG-LU005 found that adding atezolizumab to chemoradiation did not significantly reduce clinically meaningful decline at 15 months, while twice-daily radiation was consistently associated with...
A planned patient-reported...
08/27/2026
Oncology
News
Tarlatamab Reduces Symptom Burden and Treatment Side Effects in Extensive-Stage Small Cell Lung Cancer
08/27/2026
Emily Estrada
Patient-reported outcomes from the phase 3 DeLLphi-304 trial showed that tarlatamab delayed deterioration in key cancer-related symptoms and physical functioning while reducing treatment-related side-effect burden compared with standard...
Patient-reported outcomes from the phase 3 DeLLphi-304 trial showed that tarlatamab delayed deterioration in key cancer-related symptoms and physical functioning while reducing treatment-related side-effect burden compared with standard...
Patient-reported outcomes from...
08/27/2026
Oncology
News
Five-Year KEYNOTE-942 Results Show Durable Benefit With Intismeran Plus Pembrolizumab in Resected Melanoma
08/27/2026
Stephanie Holland
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase...
08/27/2026
Oncology
FDA Approval
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
08/26/2026
Emily Estrada
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multiagent systemic therapy after phase 3 RASolute 302 data showed significant...
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multiagent systemic therapy after phase 3 RASolute 302 data showed significant...
The FDA approved daraxonrasib...
08/26/2026
Oncology
News
Biomarker-Driven GUIDANCE Trial Targets HRD-Positive Small Cell Lung Cancer With Olaparib Plus Durvalumab
08/25/2026
Stephanie Holland
The phase 2 GUIDANCE trial is evaluating maintenance olaparib plus durvalumab in homologous recombination deficiency-positive advanced or metastatic small cell lung cancer after first-line chemoimmunotherapy, testing whether prospective...
The phase 2 GUIDANCE trial is evaluating maintenance olaparib plus durvalumab in homologous recombination deficiency-positive advanced or metastatic small cell lung cancer after first-line chemoimmunotherapy, testing whether prospective...
The phase 2 GUIDANCE trial is...
08/25/2026
Oncology
FDA Approval
FDA Approves Zanidatamab-Based Regimens for First-Line HER2-Positive Advanced Gastroesophageal Adenocarcinoma
08/25/2026
Stephanie Holland
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, for first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma after phase 3 HERIZON-GEA-01 data showed significant...
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, for first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma after phase 3 HERIZON-GEA-01 data showed significant...
The FDA approved zanidatamab...
08/25/2026
Oncology
News
ESMO Recommends Daraxonrasib After Chemotherapy for RAS G12–Mutant Metastatic Pancreatic Cancer
08/19/2026
Stephanie Holland
ESMO guidelines recommend daraxonrasib as a second-line treatment after chemotherapy for patients with RAS G12–mutant metastatic pancreatic cancer and ECOG performance status 0 to 1, based on phase 3 improvements in survival, response, and...
ESMO guidelines recommend daraxonrasib as a second-line treatment after chemotherapy for patients with RAS G12–mutant metastatic pancreatic cancer and ECOG performance status 0 to 1, based on phase 3 improvements in survival, response, and...
ESMO guidelines recommend...
08/19/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use